Featured Research

from universities, journals, and other organizations

Antidepressant Found To Alleviate Symptoms Of Irritable Bowel Syndrome In Adolescents

Date:
May 2, 2008
Source:
University of California - Los Angeles
Summary:
Low-dose antidepressant therapy can significantly improve the overall quality of life for adolescents suffering from irritable bowel syndrome, or IBS. The study is the first of its kind to look at the effects of amitriptyline, a tricyclic antidepressant, in the pediatric IBS population.

Researchers at Mattel Children's Hospital UCLA have found that low-dose antidepressant therapy can significantly improve the overall quality of lifefor adolescents suffering from irritable bowel syndrome, or IBS. The syndrome affects 6 percent of middle school students and 14 percent of high school kids in the United States.

Related Articles


The study, published in the May issue of the peer-reviewed Journal of Pediatrics,is the first of its kind to look at the effects of amitriptyline, a tricyclic antidepressant, in the pediatric IBS population, researchers said.

Theresearch was conductedbetween 2002 and2005 and involved 33 newly diagnosed IBS patients, including 24girls, between the ages of 12 and 18.

Irritable bowel syndromecauses discomfort in the abdomen, along with diarrhea,constipation or both. Currently, there is no cure, and treatments only lessen the symptoms.

"While research has shown that amitriptyline is effective for adults with IBS, only peppermint oil has been studied in children with this disorder in a double-blind, placebo-controlled fashion," said Dr. Ron J. Bahar, assistant clinical professor of pediatric gastroenterology at Mattel Children's Hospital UCLA and lead author of the study. "Our results show that amitriptyline significantly improves overall quality-of-life measurements in adolescents and should be a therapeutic option for these patients. We were actually surprised to reach our conclusion with a relatively small number of subjects."

The 13-week studyconsisted ofthree phases: two weeks of enrollment and symptom scoring, eight weeks of therapy withamitriptyline or a placebo, and three weeks of post-medication "washout" and symptom scoring.

Patients were randomized in a double-blinded fashion to receivethe antidepressantor a placebo and were surveyed at two, six, 10 and 13 weeksusing a symptom checklist, a pain-rating scale, a pain intensity and frequency scale, and an IBS quality-of-life questionnaire.

The results showed that patients receivingamitriptyline were more likely to experience:

  • An improvement in overallquality of lifeat six, 10 and 13 weeks.
  • A reduction in IBS-associated diarrhea atsix and 10 weeks.
  • A reduction in pain near the belly button at 10 weeks.
  • A reduction inpain in the right lower quadrant of the abdomenat six, 10 and 13 weeks.

Baharsaid that more than halfofeligiblepatients, or their parents or guardians, refused to enroll in the study because they were uncomfortable with using an antidepressant medication of any kind, citing negative reports in the media about their side effects and the Food andDrug Administration's formal 2004 "black box" warnings regarding the increased potential for suicide in children using antidepressants.

"However, the dose of AMI (amitriptyline) used in this study, as well as IBS treatment for adults, is far less than the dose to treat depression," Bahar said. "At these low levels, it could be considered a remedy to treat neuropathic pain associated with chronic pain symptoms, rather than an antidepressant or psychotropic medication."

The next stage of research will look at the long-term follow-up of these patients to determine who will continue to stay well on the medication, whose symptoms resolve spontaneously and what other medications can be used as an alternative to amitriptyline for adolescents with IBS.

The research was funded by James L. Brooks and the Diane Brooks Medical Research Foundation of the California Community Foundation, and by the pharmaceutical company AstraZeneca.

Other study authors included Dr. Brynie S. Collins, Dr. Barry Steinmetz and Dr. Marvin Ament.


Story Source:

The above story is based on materials provided by University of California - Los Angeles. Note: Materials may be edited for content and length.


Cite This Page:

University of California - Los Angeles. "Antidepressant Found To Alleviate Symptoms Of Irritable Bowel Syndrome In Adolescents." ScienceDaily. ScienceDaily, 2 May 2008. <www.sciencedaily.com/releases/2008/05/080501154222.htm>.
University of California - Los Angeles. (2008, May 2). Antidepressant Found To Alleviate Symptoms Of Irritable Bowel Syndrome In Adolescents. ScienceDaily. Retrieved October 30, 2014 from www.sciencedaily.com/releases/2008/05/080501154222.htm
University of California - Los Angeles. "Antidepressant Found To Alleviate Symptoms Of Irritable Bowel Syndrome In Adolescents." ScienceDaily. www.sciencedaily.com/releases/2008/05/080501154222.htm (accessed October 30, 2014).

Share This



More Health & Medicine News

Thursday, October 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Mind-Controlled Prosthetic Arm Restores Amputee Dexterity

Mind-Controlled Prosthetic Arm Restores Amputee Dexterity

Reuters - Innovations Video Online (Oct. 29, 2014) A Swedish amputee who became the first person to ever receive a brain controlled prosthetic arm is able to manipulate and handle delicate objects with an unprecedented level of dexterity. The device is connected directly to his bone, nerves and muscles, giving him the ability to control it with his thoughts. Matthew Stock reports. Video provided by Reuters
Powered by NewsLook.com
Google To Use Nanoparticles, Wearables To Detect Disease

Google To Use Nanoparticles, Wearables To Detect Disease

Newsy (Oct. 29, 2014) Google X wants to improve modern medicine with nanoparticles and a wearable device. It's all an attempt to tackle disease detection and prevention. Video provided by Newsy
Powered by NewsLook.com
Can Drinking Milk Lead To Early Death?

Can Drinking Milk Lead To Early Death?

Newsy (Oct. 29, 2014) Researchers in Sweden released a study showing heavy milk drinkers face an increased mortality risk from a variety of causes. Video provided by Newsy
Powered by NewsLook.com
Obama: The US Will Not 'run and Hide' From Ebola

Obama: The US Will Not 'run and Hide' From Ebola

AP (Oct. 29, 2014) Surrounded by health care workers in the White House East Room, President Barack Obama said the U.S. will likely see additional Ebola cases in the weeks ahead. But he said the nation can't seal itself off in the fight against the disease. (Oct. 29) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



    Save/Print:
    Share:

    Free Subscriptions


    Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

    Get Social & Mobile


    Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

    Have Feedback?


    Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
    Mobile: iPhone Android Web
    Follow: Facebook Twitter Google+
    Subscribe: RSS Feeds Email Newsletters
    Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins